Chemesis, First Medical Cannabis tie up to grow hemp in Puerto Rico

By Nikita Chaurasia  Date: 2019-03-20

Chemesis, First Medical Cannabis tie up to grow hemp in Puerto Rico
  • Chemesis International has continued to expand its foothold on the island with the expectation that hemp would be legalized in Puerto Rico
     
  • It would have access to about 6,000 acres of prime agricultural land in the country to cultivate hemp

Chemesis International Inc., the Canada-headquartered cannabis firm, has reportedly announced that it has teamed up with Puerto Rico-based First Medical Cannabis LLC to begin exclusive cultivation of hemp with high yields of CBD. As per trusted sources, Chemesis International would have access to 1,000 acres of prime agricultural land in Puerto Rico for hemp cultivation and would have the option to expand to an additional 5,000 acres.

Reportedly, Chemesis has continued to expand its foothold in the island-nation with the expectation that hemp would be legalized in Puerto Rico. As of today, the company has the capacity to grow high yield CBD derived from hemp in huge amounts for distribution on the island and across the mainland United States.

The Chief Executive Officer of Chemesis International, Edgar Montero was reportedly quoted saying that Puerto Rico has been in need for an agricultural revolution since the last of the sugar factories were closed on the island in the year 2000 and the much-required jobs are promised by the hemp market. The country is the perfect competitor in the hemp industry given the tropical climate of the island and the fact that it will help the Chemesis to harvest up to three crops annually as compared to one in numerous areas across the world, Montero further added.

According to a press release from Chemesis International, the company would leverage its fully compliant manufacturing plant to produce, process, and distribute hemp-derived CBD products. Moreover, the plant has the capacity to take all the hemp manufactured by First Medical and process into finished goods for sale in international and domestic markets, including the continental United States.

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...

LinkedIn confirms launch of a social audio platform to rival Clubhouse

LinkedIn confirms launch of a social audio platform to rival Clubhouse

By Nikita Chaurasia

LinkedIn, the popular employment-oriented online service, has confirmed that it is testing a social audio experience in its app which could offer users with better connectivity in their networks. Although several social media giants such as Twitter ...

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07...